Should You Buy GlaxoSmithKline plc, Hikma Pharmaceuticals Plc Or Indivior PLC?

Is GlaxoSmithKline plc (LON:GSK) a better long-term pick than Hikma Pharmaceuticals Plc (LON:HIK) or Indivior PLC (LON:INDV)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in income favourite GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) have fallen by nearly 15% over the last three months, and by 7% so far in June.

This has pushed the prospective dividend yield on Glaxo shares up to a very tempting 5.9%. Add in this year’s special dividend of 20p per share and the prospective yield rises to 7.4%.

Many private investors hold Glaxo stock for income, and it appears that a good number have been topping up following the recent falls. Glaxo was the most bought stock by customers of retail broker TD Direct last week, just ahead of a second income favourite, Royal Dutch Shell.

Should you invest £1,000 in Ashtead Group Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Ashtead Group Plc made the list?

See the 6 stocks

Glaxo is one of my own income holdings, so I’m keen to understand whether the stock is cheap, or whether the weak share price is justified by falling profits.

To help me compare Glaxo to the wider pharmaceutical sector, I’ve chosen two smaller pharma stocks, Hikma Pharmaceuticals (LSE: HIK) and the recent Reckitt Benckiser spin-off, Indivior (LSE: INDV), for comparison.

Earnings slide

The grim reality is that Glaxo’s falling share price has probably been triggered by big cuts to earnings forecasts for the next two years.

Glaxo’s forecast earnings per share for 2015 have been cut from 91.9p to 81.5p over the last three months, a fall of 10%. Over the same period, Hikma’s 2015 earnings per share forecast has been cut by 3.4%, while Indivior’s has been increased by 9.2%.

Here’s how this is reflected in each firm’s current 2015 forecast P/E:

Company

2015 forecast P/E

GlaxoSmithKline

16.6

Hikma Pharmaceuticals

20.9

Indivior

13.0

Given its yield, Glaxo doesn’t look bad value in this company. Hikma’s demanding valuation could come under threat if earnings don’t rebound in 2016.

Indivior looks cheaper but is expected to report a 54% fall in earnings per share in 2015, and a 21% decline in 2016. This is because the firm’s main product, Suboxene, a drug used to treat opioid addiction, is expected to face increased competition from cheaper generic products.

What about dividends?

Glaxo currently has the highest dividend yield in the pharmaceutical sector. Hikma and Indivior can’t really compete:

Company

2015 prospective yield

GlaxoSmithKline

5.9%

Hikma Pharmaceuticals

0.9%

Indivior

2.8%

Glaxo remains an attractive income buy, but the firm’s payout is beginning to look at little stretched, as dividend cover is expected to fall to only 1.0 this year. In contrast, Hikma has forecast dividend cover of 5.4, while Indivior’s payout should be covered about 2.7 times.

Cash is king

Historically, Glaxo has generated a lot of free cash flow, enabling the firm to fund its generous dividend and maintain R&D investment.

However, free cash flow has fallen over the last two years, and is no longer enough to cover the dividend payout. In fact, using the price to free cash flow ratio instead of P/E, Glaxo looks more expensive than both Hikma and Indivior:

Company

2014 price/free cash flow ratio

GlaxoSmithKline

22.9

Hikma Pharmaceuticals

19.0

Indivior

6.1

Today’s best buy?

While Indivior looks cheap, investors need to trust that the firm will find a way of replacing the falling profits from its Suboxene brand.

Hikma’s growth valuation is too demanding for me, and I’m happy to stick with Glaxo, which I believe will deliver medium-term profit growth as newer products gain market share.

Should you buy Ashtead Group Plc now?

Don’t make any big decisions yet.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.

And he believes they could bring spectacular returns over the next decade.

Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows...

When such enormous changes hit a big industry, informed investors can potentially get rich.

So, with his new report, Mark’s aiming to put more investors in this enviable position.

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head owns shares of GlaxoSmithKline and Royal Dutch Shell. The Motley Fool UK has recommended GlaxoSmithKline and Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Content white businesswoman being congratulated by colleagues at her retirement party
Investing Articles

Starting with £20,000, this 5-stock SIPP could generate a £1m pension pot

A seven-figure SIPP should – from a financial perspective -- help provide a comfortable retirement. Our writer looks at how…

Read more »

Businesswoman calculating finances in an office
Investing Articles

Down 35% in a year, is this FTSE 100 stock a once-in-a-decade opportunity?

Spirax Group shares have been dreadful over the last five years. But could the FTSE 100 industrial manufacturer actually be…

Read more »

Middle aged businesswoman using laptop while working from home
Investing Articles

This artificial intelligence AIM stock trades with an EV-to-EBITDA of just 4x!

Look at US markets and we’ll see artificial intelligence stocks trading with huge earnings multiples. So why is this AIM…

Read more »

A mixed ethnicity couple shopping for food in a supermarket
Investing Articles

I’ve just bought this 7.5%-yielding REIT to give me a second income

Our writer recently bought shares in a real estate investment trust (REIT) that he hopes will provide him with a…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

2 standout FTSE 100 growth shares I think are too cheap this June!

Searching for the best FTSE 100 bargain shares to buy as the summer kicks off? Here are two on Royston…

Read more »

Businessman hand stacking up arrow on wooden block cubes
Investing Articles

Up 1,300% over 5 years, this still has to be one of the cheapest stocks in the UK

Dr James Fox suggests this could be one of the cheapest stocks listed on British exchanges. But surely there’s got…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

How I’m targeting monster gains in my Stocks and Shares ISA

Edward Sheldon's buying high-quality growth stocks for his Stocks and Shares ISA in an effort to generate fantastic long-term returns.

Read more »

Businessman hand flipping wooden block cube from 2024 to 2025 on coins
Investing Articles

Why the National Grid share price fell 5% in May

Most investors wouldn't register a 5% monthly drop in a FTSE 100 stock. Happens all the time. But Harvey Jones…

Read more »